In Partnership With
 The WOLF Pick · September 14, 2026
One Launch.
$INSM
A Bigger Debate.

Brinsupri sales rose 49% quarter over quarter. The real debate is patient retention, and the pipeline adds more ways to win.

▪ 01 / THE INVESTMENT THESIS

The Launch Versus the Retention Debate

Every Monday, WOLF Financial breaks down one stock making noise for all the right reasons. One ticker. One thesis. Full breakdown.

This Week's WOLF Pick: Insmed ($INSM).

A drug launch can beat revenue expectations and still leave investors arguing about its future. Insmed is living that contradiction: Brinsupri generated $309.2 million in second-quarter sales, up 49% from the prior quarter. The question is how many patients keep taking it.

Brinsupri treats non-cystic fibrosis bronchiectasis, a chronic condition in which damaged airways struggle to clear mucus and become vulnerable to infection. The once-daily pill targets an enzyme involved in inflammatory damage. It launched in the U.S. in August 2025.

The independent research shared with WOLF Financial makes a useful distinction: a patient who pauses treatment after an insurance problem is different from one who permanently stops. Both can look like a lost patient in a model built from sales and new prescriptions.

That is a thesis to test, not a measured retention rate. The research cites physician field checks suggesting some patients restart after coverage issues are resolved. Those observations are anecdotal. They do not establish company-wide persistence, and Insmed has not supplied the definitive discontinuation figure investors want.

The slide below illustrates the research author's argument. Its field-check statistics are not audited company metrics.

▪ 02 / THE PIPELINE

More Than One Program

The commercial bar is rising. Insmed now forecasts $1.25 billion to $1.40 billion in 2026 Brinsupri revenue. Its estimate of combined peak annual sales across Brinsupri, Arikayce and investigational TPIP exceeds $14 billion. Peak sales are management's long-term ambition, not current revenue or a guaranteed outcome.

Arikayce, an inhaled antibiotic for a difficult lung infection, already contributes revenue. A July filing seeks to expand its U.S. use to newly diagnosed patients. TPIP, an investigational inhaled treatment for high blood pressure in the lungs, is in Phase 3 trials. Both programs could broaden the business; regulatory and clinical outcomes remain uncertain.

The research also points to INS1033, a wholly owned, early-stage program being developed for inflammatory diseases. The FDA cleared its initial trial application in July. Its economics could differ from licensed Brinsupri, but an early trial is a long way from an approved product.

The slide below maps that ownership distinction. Claims that investors assign the program no value are the research author's interpretation, not something observable from the share price.

▪ 03 / CATALYSTS & RISKS

What to Watch

One catalyst in the source is already complete: Japan approved Brinsupri on August 24. The next questions are commercial execution, the Arikayce review and progress through TPIP's trials. The next quarterly report should offer another test of whether prescription demand and repeat use can support the higher sales forecast.

There is an accounting caveat worth spelling out. The reported second-quarter operating loss of about $1.5 million already includes a favorable $99.8 million valuation adjustment. Removing that benefit produces roughly $101.3 million of operating loss. Calling the underlying business effectively breakeven would overstate the evidence.

The downside case is straightforward: patients stop sooner than expected, insurers make access harder, or the pipeline disappoints while development spending continues. A successful launch does not eliminate funding risk.

The useful tell is whether new starts turn into repeat prescriptions. If persistence holds and the sales outlook remains supported, the launch thesis strengthens. If revenue growth masks weak retention, the market's skepticism has substance. Track both, rather than letting a headline sales number settle the debate.

▪ 04 / OUR PARTNER

From One Stock to Broad Market Exposure

Single-company research asks whether a business can execute. Our sponsor takes a different approach, pairing broad equity exposure with an income strategy.

TappAlpha
 Partner · TappAlpha | Paid Partnership
Broad Market Exposure. Daily Options. Monthly Income Potential.

TappAlpha's TSPY combines broad U.S. equity exposure with a daily covered-call strategy that seeks income while retaining prospects for capital appreciation.

The fund sells call options that expire the same day. Premiums can support distributions, but the strategy can limit upside and does not protect investors against market losses.

Monthly distributions are not guaranteed and may include return of capital. A distribution rate is not total return. Explore the strategy, risks and standardized performance before evaluating the fund.

Explore TSPY →

Paid partnership. Full fund disclosures appear below.

Built For Wolves.

Follow WOLF Financial · Insmed earnings and pipeline update

WOLF Financial publishes The WOLF Pick for informational and educational purposes only. Nothing in this newsletter constitutes financial advice or a recommendation to buy or sell any security. Always do your own research before making investment decisions.

The research and analysis referenced in this edition was prepared by independent third-party sources and shared with WOLF Financial for informational and educational purposes. It does not constitute a recommendation or endorsement by WOLF Financial.

Important Disclosures

Paid partnership with TappAlpha. This content is for informational purposes only and is not a recommendation to buy or sell any security.

Consider TSPY’s investment objectives, risks, charges and expenses carefully before investing. The prospectus and summary prospectus contain this and other information. Obtain them at tappalphafunds.com and read them carefully before investing.

Investing involves risk, including possible loss of principal. Options can limit upside and do not protect against market losses. Distributions are not guaranteed and may include return of capital, which can reduce NAV and tax basis. Past performance does not guarantee future results.

TSPY is distributed by Foreside Fund Services, LLC.

Prospectus | Fund Documents & Standardized Performance